The San Diego-based clinical-stage company plans to utilize its srRNA technology to overcome limitations found in current prevention methods. While the existing Bacillus Calmette-Guérin vaccine protects young children, it fails to provide adequate defense for adolescents and adults, who serve as the primary drivers of pulmonary transmission.

CEO Nathaniel Wang stated that clinical data from the company’s rabies vaccine program suggests their platform can trigger robust immune responses at low doses. This research is part of a broader push by Replicate to address global health threats, including ongoing work on HIV and malaria vaccines funded by the foundation. All developments under this grant are subject to humanitarian licensing terms intended to ensure equitable access in the regions most impacted by the disease.